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Background: Lung cancer is the major cause of cancer death globally, it is often diagnosed at an advanced stage
and has one of the lowest survival rates of any type of cancer. The common interest in the field of lung cancer
research is the identification of biomarkers for early diagnosis and accurate prognosis. There is increasing evidence
to suggest that microRNAs play important and complex roles in lung cancer.
Methods: A meta-analysis was conducted to review the published microRNA expression profiling studies that
compared the microRNAs expression profiles in lung cancer tissues with those in normal lung tissues.
A vote-counting strategy that considers the total number of studies reporting its differential expression, the total
number of tissue samples used in the studies and the average fold change was employed.
Results: A total of 184 differentially expressed microRNAs were reported in the fourteen microRNA expression
profiling studies that compared lung cancer tissues with normal tissues, with 61 microRNAs were reported in at
least two studies. In the panel of consistently reported up-regulated microRNAs, miR-210 was reported in nine
studies and miR-21 was reported in seven studies. In the consistently reported down-regulated microRNAs, miR-126
was reported in ten studies and miR-30a was reported in eight studies. Four up-regulated microRNAs (miR-210,
miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently
reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis, with the other 14 microRNAs
solely reported in one or the other subset.
Conclusions: In conclusion, the top two most consistently reported up-regulated microRNAs were miR-210 and
miR-21. The results of this meta-analysis of human lung cancer microRNA expression profiling studies might provide
some clues of the potential biomarkers in lung cancer. Further mechanistic and external validation studies are
needed for their clinical significance and role in the development of lung cancer.
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Lung cancer is the leading cause of cancer death in
males and the second leading cause of cancer death
among females in 2008 globally [1,2]. Lung cancer is
often diagnosed at an advanced stage and has one of the
lowest survival rates of any type of cancer [3,4]. The
common interest in the field of lung cancer research is* Correspondence: bszhou@mail.cmu.edu.cn
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reproduction in any medium, provided the orthe identification of biomarkers for early diagnosis and
accurate prognosis [5,6], and the general starting point is
to compare the gene expression profiles between lung
cancer tissues and noncancerous/normal lung tissues.
Although many efforts to develop a robust genomic
model have been made in this area, controversy exists
for their clinical application [7].
Recently, there is increasing evidence to suggest that
microRNAs (miRNAs) play important and complex roles
in human cancers, including lung cancer [8-10]. miRNAs
are a class of small, noncoding, highly stable RNAs that
regulate mRNA and protein expression. Several studiesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lating various biological processes, such as cellular differ-
entiation, proliferation, angiogenesis, metabolism and
cancer development [11-13]. Microarray-based miRNA
profiling assays attracted more attention because they
constitute the efficient methodology to screen in parallel
for the expression of hundreds of miRNAs through ex-
tensive sample collections. With the aim at identifying
new biomarkers of lung cancer, many investigators have
carried out miRNAs expression profiling studies in cell
lines, tissue samples or serum samples [9,14,15]. Typic-
ally, dozens of miRNAs are identified to be differentially
expressed, miRNAs can be either over- or under-
expressed, depending on their target downstream genes.
Given the fact of a large number of candidate signatures,
a logical approach to identify important expression signa-
tures is to search for the intersection of those signatures
identified in multiple independent studies [16]. The chal-
lenges are how to collate the results of those miRNAs ex-
pression profiling studies, when they employed different
profiling platforms, and made use of different methods
to ascertain differential expression, for example,
normalization or significance thresholds. To address
these challenges, Griffith and Chan proposed a vote-
counting strategy to identify consistent markers when
raw data are unavailable [17,18], which gave us insights
into the meta-analysis of lung cancer miRNA expression
profiling studies.
The starting point of this meta-analysis is to collect those
published miRNAs expression profiling studies that com-
pared the miRNAs expression profiles in lung cancer tis-
sues with those in noncancerous/normal lung tissues.
Then, the above mentioned vote-counting strategy that
considers the total number of studies reporting its differen-
tial expression, the total number of tissue samples used in
the studies and the average fold change will be employed.
The consistently reported differentially miRNAs will be
presented and we will also rank the differentially expressed
up-regulated and down-regulated miRNAs.
Methods
Study selection
PubMed was used to search for lung cancer miRNA expres-
sion profiling studies published from January 2003 and May
2012 (last accessed on 15 May 2012), by means of the MeSH
terms: ‘lung neoplasms’ and ‘microRNAs’ in combination
with the keyword ‘profiling’ and ‘humans’. Eligible studies
had to meet the following criteria: (i), they were miRNA ex-
pression profiling studies in lung cancer patients; (ii), they
used tissue samples obtained from surgically resected lung
tumor and corresponding noncancerous or normal tissues
for comparison; (iii), use of miRNA microarray methods;
(iv), reporting of cut-off criteria of differentially expressed
miRNAs, and (v), validation method and validation sampleset reported. Therefore, the miRNA profiling studies using
the serum, or sputum samples of lung cancer patients or
lung cancer cell lines, or using different miRNA technologies
were excluded. Review articles and the studies comparing
miRNA expression profiles in lung squamous cell carcinoma
from those in lung adenocarcinoma were also excluded.
Data abstraction
Two investigators (PG and ZY) independently evaluated and
extracted the data with the standard protocol and with all
the discrepancies resolved by a third investigator (BZ). From
the full text and corresponding supplement information, the
following eligibility items were collected and recorded for
each study: author, journal and year of publication, location
of study, selection and characteristics of recruited lung can-
cer patients, platform of miRNA expression profiling, author
defined cut-off criteria of statistically differentially expressed
miRNAs and the list of up- and down-regulated miRNA fea-
tures, and their corresponding fold change (if available).
Ranking
Each included studies comparing miRNA expression
between lung cancer tissues and neighbouring noncan-
cerous or normal lung tissues provided a list of differen-
tially expressed miRNAs. Then, the following vote-
counting strategy based method of ranking potential mo-
lecular biomarkers, by Griffith [17] and Chan [18], was
adopted in the meta-analysis. The differentially expressed
miRNAs reported by each study were ranked according
to the following order of importance (i), number of the
studies that consistently reported the miRNA as differen-
tially expressed and with a consistent direction of change;
(ii), total number of samples for comparison in agree-
ment; (iii), average fold change reported by the studies in
agreement (only based on the subset of studies with avail-
able fold change information). All the comparisons were
stepwise made with the online bioinformatics tool
(http://jura.wi.mit.edu/bioc/tools/compare.php), and the
ranking was performed by Statistical Product and Service




A total of 137 relevant publications were indexed in
PubMed. According to the inclusion criteria and identifica-
tion of duplicate publication, only 14 independent studies
[19-32] were included in the analysis. The characteristics of
these studies are listed in Table 1 in alphabetical order of
the first author. Among the fourteen included studies, four
studies focused on lung squamous cell carcinoma, three
studies focused on lung adenocarcinoma, six studies were
about non-small cell lung cancer, and one study based on
non-specified lung cancer patients (Table 1). Reference 30
Table 1 Fourteen microarray-based human lung cancer microRNA expression profiling studies (lung cancer tissue versus normal)
First author
(reference)



















Satge I to IV
(Stage I 60%)
52 (28/24) The miRNA microarray
(Ohio State University,
version 2.0)
P< 0.001 56 6† 4†
Dacic [20] 2010 USA (Pittsburgh) NR ADC NR 12 (6/6) FlexmiR human microRNA
pool (Version 8,
Exiqon, Vedbaek, Denmark)
FC> 20 7 4 3






NSCLC NR 16 (8/8) miRCURY™ LNA microRNA







NR 8 (4/4) FC> 2 31 7 23
Jang [22] 2012 USA (Minnesota) Jan 1997 to
Sep 2008
ADC Stage I to IV
(Stage I 68.0%)






Ma [23] 2011 China (Zhejiang) NR NSCLC
(SCC:3;
ADC:3)
Stage I to IV
(Stage I 16.7%)
12 (6/6) Illuminia Technologies
“humanMI_V2”
FDR <0.1 1 1 0
Raponi [24] 2009 USA (Michigan) Oct 1991 to
Jul 2002
SCC Stage I to IV
(Stage I 55%)
71 (61/10) Ambion mirVana
Bioarray (version 2.0)
Signal intensity
(log2) >6 in at
least one group
15 13 2
Seike [25] 2009 USA (Baltimore: 15;
Minnesota:7); Japan
(Hamamatsu: 6)
2000 to 2004 NSCLC (ADC
around 78%)
Stage I to IV
(Stage I 75%)






















Wang [28] 2011 China
(Jiangsu, Nanjing
Chest Hospital)
2006 to 2008 NSCLC
(SCC:7;
ADC:16)







Xing [29] 2010 USA (Baltimore) Mar 2000 to
Jun 2003
SCC Stage I 30 (15/15) GeneChipR miRNA Array
(Affymetrix,









Stage I to IV
(Stage I 62.5%)
208 (104/104) The miRNA microarray
Chip (TJU version 1.1)
P< 0.001 43 15 28
SCC 78 (39/39) 16 10 6
ADC 130 (65/65) 17 5 12













Abbreviations: ADC, adenocarcinoma/adenosquamous carcinoma; FC, fold change; FDR, false discovery rate; miRNAs, microRNAs; NR, not reported; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma.
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histological type, and the miRNA profiles in lung squamous
cell carcinoma of reference 21 was described in a separate
publication [33], which made it possible to further explore
and compare the deregulated miRNAs in different histo-
logical type of lung cancer. Different platforms and various
statistical and bio-computational analyses have been uti-
lized in the collected profiling studies. The number of dif-
ferential miRNAs ranges from 1 to 60, with the median
20. There is one study [19] that only provided the top ten
miRNAs of the identified 56 significantly differentially
expressed miRNAs. Ten of the fourteen eligible studies
provided fold change (FC) information of differentially
expressed miRNAs. As one environmental well-known risk
factor of lung cancer is tobacco smoking, six studies pro-
vided the information of patients’ smoking status. Among
them, all the lung cancer patients in reference 19 were
current or former heavy smokers and all the lung cancer
patients in reference 22 and 25 were never smokers.
Differentially expressed miRNAs
A total of 184 differentially expressed miRNAs were
reported in the fourteen miRNA expression profiling
studies that compared lung cancer tissues with normal
tissues, with 61 miRNAs (33.2%) were reported in at
least two studies. Among the 61 differentially expressed
miRNAs, 54 miRNAs (88.5%) were with a consistent dir-
ection, 26 were reported to be up-gulated (Table 2) andTable 2 Consistently reported up-regulated miRNAs (n=26) in





miR-210 9 (19,22,24,25,26,27,29,30,32) 796
miR-21 7 (19,21,25,28,29,30,32) 448
miR-182 6 (22,24,26,27,28,32) 496
miR-31 6 (21,22,26,27,29,32) 425
miR-205 5 (26,27,28,29,30) 417
miR-200b 5 (19,25,26,28,32) 262
miR-183 4 (22,24,27,28) 388
miR-203 3 (24,26,30) 347
miR-196a 3 (22,27,28) 317
miR-708 3 (22,27,29) 301
miR-92b 3 (27,28,32) 151
miR-193b 3 (21,26,27) 149
miR-106a 2 (24,30) 279
miR-21* 2 (22,27) 271
miR-135b 2 (21,22) 222
miR-96 2 (22,23) 218
miR-17-5p 2 (24,27) 136
miR-20b 2 (24,28) 117
miR-18a 2 (26,28) 114
miR-200a 2 (24,32) 111
miR-93 2 (24,32) 111
miR-130b 2 (26,32) 108
miR-200c 2 (24,29) 101
miR-375 2 (28,32) 86
miR-20a 2 (20,24) 83
miR-18b 2 (20,26) 80
a The asterisk is part of the miRNA nomenclature system and is not linked to any fo28 down-regulated (Table 3). The seven inconsistently
reported miRNAs are listed in Table 4.
In the panel of consistently reported up-regulated miR-
NAs, miR-210 was reported in nine studies (average FC:
2.65) and miR-21 was reported in seven studies (average
FC: 4.39). In the consistently reported down-regulated miR-
NAs, miR-126 was reported in ten studies (average FC:
0.33), and miR-30a was reported in eight studies (average
FC: 0.36).
Subgroup analysis on histological type was conducted for
further comparison. In the six studies based on the tissues
from lung squamous carcinoma patients [24,26,29-31,33],
nineteen deregulated miRNAs were consistently reported
in at least two studies (8 up-regulated and 11 down-regu-
lated) with miR-210 as the most frequent reported up-regu-
lated miRNA (Table 5). In the subset of four studies about
lung adenocarcinoma [20,22,30,32], seven miRNAs were
consistently reported, with miR-210 as the most frequent
reported up-regulated miRNA (Table 6). Four up-regulated
miRNAs (miR-210, miR-21. miR-31 and miR-182) and two
down-regulated miRNAs (miR-126 and miR-145) were
consistently reported both in squamous carcinoma and
adenocarcinoma-based analysis, with the other 14 miRNAs
solely reported in one subset or the other (Tables 5 and 6).
Factors to consider for miRNAs as biomarkers
To our knowledge, no meta-analysis of miRNA profiling
studies has investigated lung cancer specially. This kindprofiling studies (lung cancer tissue versus normal)








6 449 2.65 1.51 - 5.10
6 240 4.39 1.74 - 13.60
4 357 6.34 1.85 - 19.00
5 357 2.89 1.58 - 4.80
3 141 23.20 2.99 - 54.30
4 194 3.69 1.30 - 9.80
3 317 5.94 2.11 - 11.60
0 - - -
3 317 37.50 2.10 - 101.80
3 301 3.20 1.85 - 5.50
3 151 3.71 1.54 - 6.80
2 81 4.68 2.56 - 6.80
0 - - -
2 271 2.23 2.16 - 2.30
2 222 2.29 2.28 - 2.31
2 218 171.56 2.30 - 340.81
1 65 3.80 -
1 46 5.70 -
1 46 7.80 -
1 40 1.86 -
1 40 1.68 -
1 40 1.57 -
1 30 1.66 -
2 86 5.35 2.89 - 7.80
0 - - -
0 - - -
otnote specific to this table.
Table 3 Consistently reported down-regulated miRNAs (n=28) in profiling studies (lung cancer tissue versus normal)














miR-126 10 (19,21,25,26,27, 28,29,30,31,32) 587 8 311 0.33 0.00 - 0.69
miR-30a 8 (19,21,25,26,27,28,29,31) 339 7 271 0.36 0.04 - 0.61
miR-451 6 (19,21,25,27,28,29) 265 6 265 0.37 0.01 - 0.53
miR-486-5p 5 (19,22,26,27,28) 437 4 369 0.39 0.13 - 0.53
miR-30d 5 (21,25,28,29,31) 154 5 154 0.34 0.08 - 0.57
miR-145 4 (26,28,30,32) 362 2 86 0.23 0.09 - 0.38
miR-143 4 (21,28,30,32) 310 3 102 0.33 0.13 - 0.59
miR-139-5p 3 (22,27,29) 301 3 301 0.55 0.40 - 0.64
miR-126* 3 (21,25,30) 280 2 72 0.33 0.20 - 0.45
miR-140-3p 3 (26,27,28) 179 2 111 0.29 0.17 - 0.42
miR-138 3 (25,26,32) 164 2 96 0.64 0.56 - 0.72
miR-30b 3 (25,28,29) 132 3 132 0.41 0.11 - 0.58
miR-486 3 (25,29,32) 126 3 126 0.44 0.34 - 0.53
miR-101 3 (21,27,31) 87 3 87 0.34 0.24 - 0.48
miR-125a 2 (24,30) 279 0 - - -
miR-198 2 (27,30) 273 1 65 0.25 -
miR-144* 2 (22,27) 271 2 271 0.31 0.14 - 0.48
miR-140 2 (30,32) 248 1 40 0.66 -
miR-218 2 (22,32) 246 2 246 0.61 0.60 - 0.62
miR-32 2 (20,30) 220 0 - - -
miR-338-3p 2 (26,27) 133 1 65 0.20 -
miR-99a 2 (27,28) 111 2 111 0.31 0.20 - 0.42
miR-195 2 (26,29) 98 1 30 0.53 -
miR-497 2 (26,29) 98 1 30 0.66 -
miR-30c 2 (25,29) 86 2 86 0.58 0.54 - 0.61
miR-130a 2 (21,27) 81 2 81 0.46 0.45 - 0.46
miR-16 2 (28,29) 76 2 76 0.37 0.18 - 0.57
miR-139 2 (29,32) 70 2 70 0.53 0.49 - 0.58
a The asterisk is part of the miRNA nomenclature system and is not linked to any footnote specific to this table.
Guan et al. Journal of Experimental & Clinical Cancer Research 2012, 31:54 Page 5 of 8
http://www.jeccr.com/content/31/1/54of systematic review has been proved to be useful in ex-
ploring candidate miRNA biomarkers in human colorec-
tal cancer [34]. The present study suggested several
promising miRNAs that have been consistently reported
with average more than 2-fold change. Their potential
targets may provide a clue to the role of miRNAs in
tumorigenesis and the underlying mechanisms.Table 4 Inconsistently reported miRNAs (n=7) in










miR-224 " 24,27 136 3.4
# 30 208 -
miR-9 " 22,27 271 8.59
# 30 208 -
miR-150 " 30 208 -
# 28,32 86 0.38
miR-219-1 " 19 52 1.6
# 30 208 -
miR-125a-5p " 31 6 1.56
# 26,29 98 0.62
miR-429 " 26 68 -
# 29 30 0.50
miR-24-2* " 21 16 2.33
# 27 65 0.5
a The asterisk is part of the miRNA nomenclature system and is not linked to
any footnote specific to this table.There are several factors needed to be considered
when choosing miRNAs as candidate clinical biomarkers
of lung cancer. First, the biological complexities should
be well understood. A single miRNA may have many
targets, and also, a specific mRNA may be regulated by
multiple different miRNAs [35]. More understanding of
molecular mechanisms that can mediate miRNA dysre-
gulations and the targets of the miRNAs would advance
their use in clinical settings.
Second, there should be sufficient information about
their pattern of expression in different kinds of specimens
in target populations. The release mechanism of miRNAs
can be via tumor-derived microvesicles or exosomes
[36,37]. It has been indicated that circulating miRNAs in
plasma could be more tissue-specific than tumor-specific
[8,38], thus our study focused on the profiling studies that
compared miRNA profiles in lung cancer tissues with
those in normal lung tissues. Boeri and colleagues found
that miRNAs deregulated in tissue specimens were rarely
detected in plasma samples, which further strengthened
the high tissue-specificity of miRNAs and suggested the
predictive role of plasma miRNAs independent from tis-
sue specimens [19]. In the context of the inconsistent
profiles between tissue-based and plasma-based result,
however, some consistently reported miRNAs in tissue-
based profiling studies, for example, a panel of miR-21,





No. of studies with
same direction
(reference)
Total number of tissue
samples tested








Up-regulated miR-210 4 (24,26,29,30) 247 1 30 2.37 -
miR-203 3 (24,26,30) 217 0 - - -
miR-205 3 (26,29,30) 176 1 30 2.99 -
miR-21 3 (29,30,33) 116 2 38 2.53 1.74 - 3.31
miR-31 3 (26,29,33) 106 2 38 4.42 1.58 - 7.26
miR-182 2 (24,26) 139 0 - - -
miR-200c 2 (24,29) 101 1 30 1.66 -
miR-18a 2 (26,33) 76 1 8 2.24 -
Down-regulated miR-126 4 (26,29,31,33) 112 3 44 0.18 0.00 - 0.42
miR-30a 4 (26,29,31,33) 112 3 44 0.28 0.11 - 0.53
miR-30d 3 (29,31,33) 44 3 44 0.33 0.22 - 0.54
miR-195 2 (26,29) 98 1 30 0.53 -
miR-497 2 (26,29) 98 1 30 0.66 -
miR-126* 2 (30,33) 86 1 8 0.16 -
miR-143 2 (30,33) 86 1 8 0.24 -
miR-145 2 (26,33) 76 1 8 0.48 -
miR-451 2 (29,33) 38 2 38 0.37 0.22 - 0.53
miR-30b 2 (29,33) 38 2 38 0.50 0.48 - 0.53
miR-101 2 (31,33) 14 2 14 0.34 0.29 - 0.39
a The asterisk is part of the miRNA nomenclature system and is not linked to any footnote specific to this table. SCC, squamous cell carcinoma.
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based studies to confirm their diagnostic value in the diag-
nosis of lung cancer with solitary pulmonary nodules [39].
Future studies that based on parallel plasma and tissue
samples may provide more solid evidence. For the
included profiling studies in which adjacent corresponding
normal lung tissue served as an expression baseline, we
need to know that adjacent appearing morphologically
normal tissue may contain molecular changes associated
with cancer [40,41].
Third, rigorous validation and demonstration of repro-
ducibility in an independent population are necessary to
confirm the predictive value of miRNAs. One of the
most frequently investigated miRNAs is miR-21, it ranks
second among consistently reported up-regulated miR-
NAs in this meta-analysis, it has been also reported to
be associated with prognosis in several kinds of cancer
[42-44]. From the prognostic point of view, over expres-
sion of miR-21 has been reported to be independently
associated with reduced survival of pancreatic ductal












Up-regulated miR-210 3 (22,30,32) 376
miR-182 2 (22,32) 246
miR-31 2 (22,32) 246
miR-21 2 (30,32) 170
Down-regulated miR-218 2 (22,32) 246
miR-145 2 (30,32) 170
miR-126 2 (30,32) 170
ADC, adenocarcinoma/adenosquamous carcinoma.associated with poor survival of colon adenocarcinoma
in both the training cohort (US test cohort of 84 patients
with incident colon adenocarcinoma, recruited between
1993 and 2002) and validation cohort (independent
Chinese cohort of 113 patients recruited between 1991
and 2000) [44]. However, when expression of miR-21,
miR-29b, miR-34a/b/c, miR-155, and let-7a was determined
by quantitative real-time PCR in formalin-fixed paraffin-
embedded tumor specimens from 639 patients who partici-
pated in the International Adjuvant Lung Cancer Trial
(IALT), there was a deleterious borderline prognostic effect
of lowered miR-21 expression [45].
Conclusions
In conclusion, the top two most consistently reported up-
regulated miRNAs were miR-210 and miR-21. The results
of this meta-analysis of human lung cancer miRNA ex-
pression profiling studies might provide some clues of the
potential biomarkers in lung cancer. Further mechanistic
and external validation studies are needed for their clinical
significance and role in the development of lung cancer.rofiling studies (lung ADC tissue versus normal)





Mean fold change Range
2 246 1.96 1.75 - 2.17
2 246 2.03 1.85 - 2.22
2 246 1.83 1.60 - 2.05
1 40 2.56 -
2 246 0.61 0.60 - 0.62
1 40 0.38 -
1 40 0.46 -
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